Napredna pretraga

Pregled bibliografske jedinice broj: 420310

Antibodies targeting modified citrullinated vimentin in patients with psoriatic arthritis


Tešija-Kuna, Andrea; Miler, Marijana; Grazio, Simeon; Grubišić, Frane; Vukasović, Ines; Perić, Porin
Antibodies targeting modified citrullinated vimentin in patients with psoriatic arthritis // Clinical Chemistry and Laboratory Medicine / Siest, Gerard (ur.).
Berlin: Walter de Gruyter, 2009. str. S117-S117 (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
Antibodies targeting modified citrullinated vimentin in patients with psoriatic arthritis

Autori
Tešija-Kuna, Andrea ; Miler, Marijana ; Grazio, Simeon ; Grubišić, Frane ; Vukasović, Ines ; Perić, Porin

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Clinical Chemistry and Laboratory Medicine / Siest, Gerard - Berlin : Walter de Gruyter, 2009, S117-S117

Skup
18th IFCC - EFCC European Congress of Clinical Chemistry and Laboratory Medicine

Mjesto i datum
Innsbruck, Austrija, 7-11.06.2009

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Rheumatoid arthritis; citrullinated vimentin; psoriatic arthritis

Sažetak
Background: Recently it has been found that antibodies against modified citrullinated vimentin (anti-MCV) have comparable performance in diagnosis of rheumatoid arthritis (RA) as the antibodies targeting citrullinated peptides (anti- CCP). While anti-CCP is present in up to 15% of psoriatic arthritis (PsA) patients, the prevalence of anti-MCV in PsA patients has been poorly investigated. Our objective was to determine the prevalence and significance of anti MCV antibodies in patients with PsA. Methods: The study included 56 patients with PsA (29 male, 27 female, mean age 57± ; 12 years). Clinical features, disease activity and functional ability were noted by experienced rheumatologist. Serum samples of all patients were analyzed for anti-MCV antibodies using commercially available ELISA (Orgentec Diagnostika). Anti-CCP antibodies with ELISA (Euroimmun) and RF with latex immunoturbidimetry were also determined in all patients. Results: Anti-MCV antibodies were positive in 2/56 (3.6%) PsA patients. In one patient anti-MCV level was medium/high while in other borderline. Both patients had asymmetric polyarthritis, dactylitis and were anti-CCP and RF negative. five clinical types of PsA. No correlation between anti-MCV levels and disease activity variables or results of Health Assessment Questionnaire (HAQ) was found. Anti-CCP antibodies were negative in all patients. Conclusions: According to our findings the anti-MCV antibodies can be detected in a small proportion of PsA patients. Although the presence of anti-MCV in these patients with polyarthritic disease could presume psoriasis with concomitant RA, most of the clinical characteristics favor PsA as the primary diagnosis.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Farmacija



POVEZANOST RADA


Projekt / tema
134-0000000-3531 - Psorijatični artritis - epidemiologija i čimbenici rizika progresije (Simeon Grazio, )
134-0061245-0205 - Hemoreološki poremećaji u kroničnim bolestima (Nada Vrkić, )
134-1340227-0200 - Upala i udio farmakogenetike u razvoju i ishodu akutnih i kroničnih bolesti (Ana-Maria Šimundić, )

Ustanove
KBC "Sestre Milosrdnice"